Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, vol.24, no.2, pp.254-259, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 24 Issue: 2
- Publication Date: 2021
- Doi Number: 10.1111/1756-185x.14034
- Journal Name: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
- Page Numbers: pp.254-259
- Keywords: antirheumatic therapy, anti‐, tumor necrosis factor therapy, hepatitis B, hepatitis B virus reactivation, hepatitis B virus screening, VIRUS HBV REACTIVATION, OCCULT CARRIERS, PREVENTION, GUIDELINES, SAFETY
- Karadeniz Technical University Affiliated: Yes
Abstract
Objective The purpose of this study was to determine hepatitis B virus (HBV) screening rates in patients receiving anti-tumor necrosis factor (TNF)-alpha therapy and the frequency of HBV reactivation in patients with resolved hepatitis B virus infection (hepatitis B surface antigen [HBsAg] negative, hepatitis B core antibody [Anti-HBc] positive).